Related Experiment Video
Updated: Mar 21, 2026
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Recent developments in the use of immunotherapy in non-small cell lung cancer
Mariacarmela Santarpia1, Elisa Giovannetti2,3, Christian Rolfo4
1a Medical Oncology Unit, Department of Human Pathology 'G. Barresi' , University of Messina , Messina , Italy.
Introduction:
Targeted therapies have significantly improved the prognosis of subsets of patients with advanced non-small-cell lung cancer (NSCLC) harboring somatically activated oncogenes, such as mutant EGFR and rearranged ALK. However, the efficacy of these agents is limited by the development of acquired resistance which occurs after variable periods of time. Therefore, there is an urgent need for novel therapeutic strategies to achieve long lasting disease control, as well as new therapies for those patients without targetable driver mutations. A deeper understanding of interactions between the immune system and tumor cells has led to the development of a number of immunotherapeutic agents.
Areas Covered:
We review current data on immunotherapy for lung cancer treatment, with a focus on checkpoint inhibitors and therapeutic vaccines. References for this review were identified through searches of PubMed, congress proceedings and reference lists from key original and review papers. Expert commentary: While most vaccines have been unsuccessful, inhibitors of specific immune checkpoints, including CTLA-4 and PD-1/PD-L1 pathway, have shown significant clinical activity and manageable toxicities and recently, two anti-PD-1 monoclonal antibodies have been approved by the FDA for treatment of patients with advanced NSCLC. Identification of reliable predictive biomarkers for patient selection and novel rational combinations are currently active areas of research to further improve the efficacy of immunotherapy.
Insights
Immunotherapy, particularly checkpoint inhibitors targeting CTLA-4 and PD-1/PD-L1, offers new hope for advanced non-small-cell lung cancer (NSCLC) patients. Research continues to identify biomarkers and combinations to enhance immunotherapy effectiveness.
Area of Science:
- Oncology
- Immunology
- Translational Medicine
Background:
- Targeted therapies improve outcomes for advanced non-small-cell lung cancer (NSCLC) with specific oncogenes (e.g., EGFR, ALK).
- Acquired resistance limits the long-term efficacy of targeted therapies, necessitating novel treatment strategies.
- Understanding tumor-immune interactions has spurred the development of immunotherapeutic agents for NSCLC.
Purpose of the Study:
- To review current immunotherapy data for lung cancer treatment.
- To focus on the efficacy and application of checkpoint inhibitors and therapeutic vaccines.
- To highlight recent advancements and future research directions in NSCLC immunotherapy.
Main Methods:
- Literature review of PubMed, congress proceedings, and key reference papers.
- Analysis of clinical data on immunotherapy agents, including checkpoint inhibitors and vaccines.
- Expert commentary on the current state and future prospects of lung cancer immunotherapy.
Main Results:
- Most therapeutic vaccines have shown limited success in lung cancer treatment.
- Immune checkpoint inhibitors targeting CTLA-4 and the PD-1/PD-L1 pathway demonstrate significant clinical activity and manageable toxicity.
- Two anti-PD-1 monoclonal antibodies are FDA-approved for advanced NSCLC, indicating a breakthrough in immunotherapy.
Conclusions:
- Immune checkpoint inhibitors represent a promising therapeutic avenue for advanced NSCLC.
- Further research is crucial for identifying predictive biomarkers and optimizing rational combinations to improve immunotherapy efficacy.
- Novel strategies are needed to overcome resistance and benefit patients lacking targetable driver mutations.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...